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Abstract Human articular chondrocytes modulated away from 
their original phenotype by serial subcultures in monolayer 
differentially express mRNAs for endopeptidases. The mRNAs 
for the cathepsins B and L are extremely low in differentiated 
cells, but are soon expressed in parallel with the loss of the 
differentiated state. In contrast, the mRNA for collagenase-1 is 
strongly expressed by differentiated chondrocytes and declines 
rapidly following phenotypic modulation. The mRNA for 
stromelysin-1 and the tissue inhibitor of metalloproteinases-2 is 
high and does not appreciably change after modulation. 
Chondrocyte activation induced by alteration of its original 
phenotype leads to the expression of endopeptidases in a way that 
markedly differs from that induced by cytokines. The results are 
relevant to cartilage catabolism in osteoarthritis and suggest a 
prominent role of fibroblastic metaplasia on the part of the 
chondrocytes as a mechanism of expressing catabolic endopepti-
dases. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Most of the research on chondrocyte-mediated breakdown 
of articular cartilage has essentially focused on the action of 
metalloproteinases released after cell stimulation by cytokines 
[1,2], while other endogenous enzymes have received less at-
tention [3,4]. Studies from this laboratory have shown that 
phenotypic modulat ion of articular chondrocytes results in 
the biosynthesis and release of high amounts of cathepsin B. 
This enzyme has been proposed to be a marker of the 'dedif-
ferentiated' chondrocyte phenotype [5] and its secretion was 
shown to depend directly on protein synthesis [6]. Phenotypic 
modulat ion of chondrocytes dramatically stimulated the secre-
tion and intracellular accumulation of active cathepsin B, 
while the extracellular activity of collagenase-1 was even sup-
pressed [7]. On the other hand, cell stimulation by interleukin-
1(3 resulted in a large increase of extracellular collagenase 
activity, while the secretion of cathepsin B was not affected 
and its intracellular pool was only moderately increased [7]. 
The role of cathepsin B in sustaining the chronicity of osteo-
arthritis, by acting as an antagonist of cartilage regeneration, 
has been documented in a study with human osteoarthritic 
articular cartilage [8,9]. These ex vivo results also pointed to 
the similarity between osteoarthritic and artificially modulated 
chondrocytes and suggested fibroblastic metaplasia as a plau-
sible mechanism for cathepsin B induction [9]. 
Since our previous studies were based on protein (enzyme 
activity) assays, the question arose whether the gene expres-
sion of the involved enzymes correlated with the protein find-
ings. In the present study we analyzed the m R N A levels for 
the cathepsins B and L, collagenase-1, stromelysin-1 and 
TIMP-2 in human articular chondrocytes phenotypically 
modulated by serial subcultures. As an internal control, re-
sults were compared to those of type I collagen m R N A ex-
pression, for which data are known from the literature. 
2. Materials and methods 
2.1. Cell isolation and culture 
Chondrocytes were prepared 8 h postmortem from cartilage pooled 
from both femoral heads and condyli of a healthy male individual 
aged 25 years according to methods detailed elsewhere [9]. Monolayer 
cultures were established at a density of 2-10G cells/25 cm2 culture 
flasks in Dulbecco's modified Eagle's medium containing 10% fetal 
calf serum. Subculturing was performed by replating in monolayer 
after trypsinization. 
2.2. RNA extraction, probes and Northern blot analysis 
Total RNA was extracted with commercial kits provided by QIA-
GEN. Cells were harvested by trypsinization, pelleted by centrifuga-
tion, resuspended in lysis buffer, homogenized with the QIAshredder 
method and RNA was extracted using the RNeasy midi RNA system. 
After heat-denaturation, equal amounts of total RNA (10.6 ug/lane) 
from primary culture and subcultures were separated electrophoreti-
cally in 2.6 M formaldehyde, 1% agarose gels and transferred to nylon 
membranes using a vacuum blotting system (Vacu Gene TMXL, 
Pharmacia) followed by exposure to ultraviolet light for crosslinking. 
cDNA clones for human cathepsin B (250 bp), human collagenase-1 
(210 bp), human tissue inhibitor of metalloproteinases-2 (300 bp) and 
human type I collagen cd(I) chain (230 bp) had previously been ob-
tained by a subtractive cDNA cloning approach [10]. cDNA clones 
for human prostromelysin-1 (780 bp) and human cathepsin L (1345 
bp) were kindly provided by Prof. H. Nagase and Prof. B. Wie-
deranders, respectively. A cDNA fragment of human glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was used as an internal stand-
ard to compensate for differences in sample loading. cDNAs were 
labeled with [32P]deoxycytidine-5'-triphosphate using a random prim-
er labeling kit (Promega). After 5-6 h of prehybridization the mem-
branes were hybridized with 32P-labeled DNA probes for 14-16 h, 
then washed 3 times each with 2X sodium chloride sodium citrate 
(SSC) containing 0.1% sodium dodecyl sulfate (SDS) for 30 min at 
room temperature and with 1XSSC/0.1% SDS for 30 min at 55°C. 
Autoradiography was carried out at — 70°C using an Agfa Curix 
Ortho HTA film and an intensifying screen for 1 or 4 days. Nylon 
membranes were reprobed with the appropriate cDNAs after strip-
ping by boiling in 0.5% SDS/0.1 X SSC buffer for 20 min. Images were 
quantified using an electrophoresis data software system (ONE-
Dscan, Billerica, MA, USA). 
*Corresponding author. Fax: (41) (1) 255-37-25. 
E-mail: baici@ruz.unizh.ch 
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3. Results 
H u m a n articular chondrocytes were phenotypically modu-
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Fig, 1. Northern blot analysis of mRNA expression by human articular chondrocytes phenotypically modulated by subcultures. The intensity 
of the bands was determined by scanning densitometry of autoradiography films. To compensate for small variations in sample loading, results 
were normalized to the GAPDH mRNA of the same lane after exactly the same exposure and are shown as per cent of the band intensity 
ratio. Numbers on the top of the bars show the actual values. ND = not determined. 
lated by serial monolayer subcultures as detailed previously 
for rabbit chondrocytes [5]. By measuring the enzymatic ac-
tivity (data not shown), we confirmed that cathepsin B is a 
typical marker of the 'dedifferentiated' phenotype also in hu-
man articular chondrocytes. Namely, the intracellular pool of 
cathepsin B as well as its secretion increased dramatically 
parallel with the loss of the differentiated state of the cells 
and with a gradual morphological change from rounded-pol-
ygonal to a fibroblast-like type. mRNA was analyzed by the 
Northern blot method in primary cultures, up to the fifth 
subculture, and probed with cDNAs for cathepsin B, cathep-
sin L, collagenase-1, stromelysin-1, type I collagen and TIMP-
2 (Fig. 1). Day 3 in Fig. 1 means the third day after the 
beginning of the cell isolation procedure from cartilage. This 
represents the first time-point at which the chondrocytes were 
free of debris and formed a uniform cell population with 
rounded morphology while still retaining the original bio-
chemical phenotype. At Day 6 all cells were adherent and 
had begun to develop a fibroblast-like morphology. Freshly 
isolated chondrocytes hardly expressed detectable levels of 
cathepsin B and L mRNA. Expression of the two cathepsins 
became apparent after subculturing the cells and reached con-
siderable levels in later subcultures. As an important internal 
control, type I collagen, previously shown to parallel the loss 
of chondrocytic differentiated functions [11,12], showed a sim-
ilar pattern of expression. In fact, the mRNA level for the 
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a 1(1) collagen chain was zero in differentiated chondrocytes 
and increased to a maximum response in the fifth subculture. 
Similar results have been reported for human fetal epiphyseal 
chondrocytes [13] and for bovine articular chondrocytes 
[14,15]. Collagenase-1 showed an opposite trend with respect 
to the two cathepsins and type I collagen: its mRNA de-
creased rapidly when the cells were passaged into the first 
subculture and was very low in the fifth subculture. Strome-
lysin-1 was strongly expressed, but did not show appreciable 
variations of its mRNA from the primary culture up to the 
fifth subculture. As previously noted by Stetler-Stevenson et 
al. [16] and Zafarullah et al. [17], TIMP-2 showed two tran-
scripts (3.5 and 1.0 kb, respectively), and data in Fig. 1 refer 
to the major (3.5 kb) transcript. The mRNA for TIMP-2 was 
highly expressed in subcultures 1-5 showing a consistent trend 
to be slightly higher in subcultures 3-5 with respect to sub-
cultures 1-2. Only a few cells were available for experiments 
with primary cultures, therefore some measurements could 
not be performed (ND in Fig. 1). 
4. Discussion 
In this paper we use the term 'phenotypic modulation' [18], 
others prefer 'dedifferentiation' [13,19], to describe the prop-
erty of articular chondrocytes to synthesize type I collagen 
and cathepsin B under monolayer culture conditions, and to 
revert to the normal state with the production of type II 
collagen but no cathepsin B after transfer to a 3-dimensional 
culture system. We emphasize that in monolayer culture chon-
drocytes are not transformed into or overgrown by fibro-
blasts. Rather, the cells assume morphological and biochem-
ical aspects resembling those of fibroblasts, a property also 
referred to as 'fibroblastic metaplasia'. Previous studies from 
this laboratory [9] demonstrated that osteoarthritic chondro-
cytes share with chondrocytes that are artificially modulated 
away from their original phenotype [5] the common property 
of expressing high levels of cathepsin B. On the basis of en-
zyme activity measurements, we pointed out that chondrocyte 
activation through the action of cytokines or by phenotypic 
modulation results in a completely different expression pattern 
for key enzymes such as collagenase-1 and cathepsin B [7]. 
Moreover, the differentiated chondrocyte did not secrete ap-
preciable amounts of cathepsin B, but secreted high levels of 
collagenase-1, while the phenotypically modulated chondro-
cyte showed the opposite trend [5,7]. The results of this study 
confirmed, at the transcriptional level, the trends observed for 
enzymatic activity. In addition, cathepsin L, hitherto not re-
ported from human articular chondrocytes, was shown to be 
expressed in a way similar to cathepsin B, being also a prod-
uct of cells modulated away from their original phenotype. 
Conversely, stromelysin-1 did not show macroscopic changes 
and can be considered to be a constitutive, housekeeping en-
zyme, not responsive to alterations due to phenotypic chon-
drocyte modulation, although being sensitive to cytokine stim-
ulation [20]. The high, persistent expression of TIMP-2 during 
several subcultures of the chondrocytes fully agrees with the 
result by Zafarullah et al. that this inhibitor is constitutively 
expressed in normal as well as in osteoarthritic chondrocytes 
[17]. 
Information pooled from this and our previous contribu-
tions [5-9], suggests that chondrocyte activation in osteoar-
thritis cannot only occur through cytokine stimulation, but 
also through a cytokine-independent mechanism based on fi-
broblastic metaplasia. We proposed earlier that the two routes 
of chondrocyte activation can either coexist or represent tem-
porarily distinct episodes [7]. This concept was reinforced by 
ex vivo studies on osteoarthritic human cartilage [8,9] that 
highlighted the role of cathepsin B as a decisive factor in 
maintaining the chronic character of osteoarthritis. Further 
support for the role of cathepsin B proposed by us comes 
from a recent investigation in a rabbit model of osteoarthritis 
[21]. On the basis of the evidence accumulated to date, it 
seems reasonable to assume that destructive processes in os-
teoarthritis are dominated by cytokine-induced metalloendo-
peptidases during episodes of joint inflammation. On the oth-
er hand, repair phases are soon initiated to compensate for the 
matrix loss, but are unsuccessful through the action of ca-
thepsin B expressed by phenotypically modulated chondro-
cytes, an event that can occur in the absence of cytokines. 
The fact that the two routes of chondrocyte activation lead 
to transcriptional and translational expression of cysteine and 
matrix metalloproteinases relevant to cartilage catabolism in 
opposite ways, may have not only pathogenetic, but also 
pharmacological implications. 
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